Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers.
Academic Medical Centers
Anti-Bacterial Agents
/ pharmacology
Cephalosporins
/ pharmacology
Enterobacteriaceae
/ drug effects
Gram-Negative Bacterial Infections
/ microbiology
Hospitalization
Humans
Microbial Sensitivity Tests
Pneumonia, Bacterial
/ microbiology
Pseudomonas aeruginosa
/ drug effects
Tazobactam
/ pharmacology
United States
beta-Lactamase Inhibitors
/ pharmacology
E. coli
ESBL
Enterobacteriaceae
Klebsiella pneumoniae
MDR
Multidrug resistance
Pseudomonas aeruginosa
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
27
09
2018
revised:
20
11
2018
accepted:
24
11
2018
pubmed:
16
1
2019
medline:
25
7
2019
entrez:
16
1
2019
Statut:
ppublish
Résumé
Pseudomonas aeruginosa (n = 1531) and Enterobacteriaceae (n = 2373) clinical isolates from hospitalized patients with pneumonia were collected from 31 US medical centers during 2015-2017. Isolates were susceptibility tested against ceftolozane-tazobactam and comparators by broth microdilution. Results from intensive care unit (ICU) patients and patients with ventilator-associated bacterial pneumonia (VABP) were analyzed separately. Ceftolozane-tazobactam was very active against P. aeruginosa (MIC
Identifiants
pubmed: 30642717
pii: S0732-8893(18)30425-5
doi: 10.1016/j.diagmicrobio.2018.11.021
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
beta-Lactamase Inhibitors
0
ceftolozane, tazobactam drug combination
0
Tazobactam
SE10G96M8W
Types de publication
Journal Article
Langues
eng
Pagination
93-102Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.